Is Botulinum Toxin Effective in Treating Orofacial Neuropathic Pain Disorders? A Systematic Review.
botulinum toxin type A
essential trigeminal neuralgia
orofacial neuropathic disorders
pain
quality of life
Journal
Toxins
ISSN: 2072-6651
Titre abrégé: Toxins (Basel)
Pays: Switzerland
ID NLM: 101530765
Informations de publication
Date de publication:
01 09 2023
01 09 2023
Historique:
received:
11
08
2023
revised:
26
08
2023
accepted:
30
08
2023
medline:
28
9
2023
pubmed:
27
9
2023
entrez:
27
9
2023
Statut:
epublish
Résumé
The aim of this paper is to provide a systematic review of the literature regarding the clinical use of botulinum toxin (BTX) to treat various orofacial neuropathic pain disorders (NP). A comprehensive literature search was conducted using Medline, Web of Science, and the Cochrane Library databases. Only randomized clinical trials (RCT) published between 2003 and the end of June 2023, investigating the use of BTX to treat NP, were selected. PICO guidelines were used to select and tabulate the articles. A total of 6 RCTs were selected. Five articles used BTX injections to treat classical trigeminal neuralgia, and one to treat post-herpetic neuralgia. A total of 795 patients received BTX injections. The selected studies utilised different doses and methods of injections and doses. All the selected studies concluded superiority of BTX injections over placebo for reducing pain levels, and 5 out 6 of them highlighted an improvement in the patient's quality of life. Most of the studies reported transient and mild side effects. There is evidence of the efficacy of BTX injections in orofacial pain management. However, improved study protocols are required to provide direction for the clinical use of BTX to treat various orofacial neuropathic pain disorders.
Sections du résumé
BACKGROUND
The aim of this paper is to provide a systematic review of the literature regarding the clinical use of botulinum toxin (BTX) to treat various orofacial neuropathic pain disorders (NP).
METHODS
A comprehensive literature search was conducted using Medline, Web of Science, and the Cochrane Library databases. Only randomized clinical trials (RCT) published between 2003 and the end of June 2023, investigating the use of BTX to treat NP, were selected. PICO guidelines were used to select and tabulate the articles.
RESULTS
A total of 6 RCTs were selected. Five articles used BTX injections to treat classical trigeminal neuralgia, and one to treat post-herpetic neuralgia. A total of 795 patients received BTX injections. The selected studies utilised different doses and methods of injections and doses. All the selected studies concluded superiority of BTX injections over placebo for reducing pain levels, and 5 out 6 of them highlighted an improvement in the patient's quality of life. Most of the studies reported transient and mild side effects.
CONCLUSION
There is evidence of the efficacy of BTX injections in orofacial pain management. However, improved study protocols are required to provide direction for the clinical use of BTX to treat various orofacial neuropathic pain disorders.
Identifiants
pubmed: 37755967
pii: toxins15090541
doi: 10.3390/toxins15090541
pmc: PMC10535201
pii:
doi:
Substances chimiques
Botulinum Toxins
EC 3.4.24.69
Types de publication
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
BJU Int. 2008 Feb;101(3):366-70
pubmed: 18184328
BMJ. 2015 Jun 08;350:h3089
pubmed: 26055193
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):1823-1828
pubmed: 32961514
Iran J Neurol. 2019 Jul 6;18(3):99-107
pubmed: 31749930
J Oral Facial Pain Headache. 2022 Winter;36(1):6-20
pubmed: 35298571
Spinal Cord Ser Cases. 2019 Sep 18;5:77
pubmed: 31632735
Pain. 2020 Sep 1;161(9):1976-1982
pubmed: 32694387
J Headache Pain. 2017 Aug 10;18(1):81
pubmed: 28799056
Cranio. 2008 Apr;26(2):126-35
pubmed: 18468272
J Headache Pain. 2013 Nov 19;14:92
pubmed: 24251833
Br J Anaesth. 2019 Aug;123(2):e385-e396
pubmed: 31208761
J Res Med Sci. 2014 Feb;19(2):106-11
pubmed: 24778662
Cephalalgia. 2018 Jan;38(1):1-211
pubmed: 29368949
Cephalalgia. 2012 Apr;32(6):443-50
pubmed: 22492424
J Headache Pain. 2016 Dec;17(1):63
pubmed: 27377706
Lancet Neurol. 2016 May;15(6):555-65
pubmed: 26947719
Neurology. 2009 Apr 28;72(17):1473-8
pubmed: 19246421
Pain Med. 2006 Jan-Feb;7(1):16-24
pubmed: 16533192
J Oral Facial Pain Headache. 2021 Fall;35(4):288-296
pubmed: 34990497
Toxins (Basel). 2020 Jun 15;12(6):
pubmed: 32549196
Clin Anat. 2022 Nov;35(8):1100-1106
pubmed: 35655442
Syst Rev. 2021 Mar 29;10(1):89
pubmed: 33781348
Neurotoxicology. 2005 Oct;26(5):785-93
pubmed: 16002144
Cleve Clin J Med. 2023 Jun 1;90(6):355-362
pubmed: 37263669
Clin J Pain. 2013 Oct;29(10):857-64
pubmed: 23370074
Clin Neuropharmacol. 2013 Sep-Oct;36(5):146-50
pubmed: 24045604
J Anat. 2023 Sep;243(3):467-474
pubmed: 36988105
Toxins (Basel). 2022 Apr 27;14(5):
pubmed: 35622555
Rev Neurol (Paris). 2020 May;176(5):325-352
pubmed: 32276788
J Spinal Cord Med. 2022 Sep;45(5):651-655
pubmed: 33263489
Aust Prescr. 2018 Jun;41(3):60-63
pubmed: 29921999
J Headache Pain. 2014 Sep 27;15:65
pubmed: 25263254
Ann Neurol. 2016 Apr;79(4):569-78
pubmed: 26814620
J Pain Res. 2019 Jul 17;12:2177-2186
pubmed: 31410051
Toxicon. 1997 Sep;35(9):1373-412
pubmed: 9403963
Pain Med. 2010 Dec;11(12):1827-33
pubmed: 21134121
Ann Neurol. 2008 Sep;64(3):274-83
pubmed: 18546285
Lancet Neurol. 2015 Feb;14(2):162-73
pubmed: 25575710
J Clin Epidemiol. 2009 Oct;62(10):1006-12
pubmed: 19631508
Cranio. 2012 Apr;30(2):95-102
pubmed: 22606852
Clin Neuropharmacol. 2002 Sep-Oct;25(5):260-2
pubmed: 12410057
Rev Neurol (Paris). 2019 Jan - Feb;175(1-2):46-50
pubmed: 30318260